AML Genomic Testing: Efficiency Gains
- A new quality advancement project shows that using a flow cytometry-triggered genomic testing algorithm, along with automated laboratory processes, can greatly reduce the time it takes to get...
- As AML classification increasingly relies on identifying genetically distinct subtypes, targeted therapies are being used earlier in treatment.
- The London Health Science Center in Ontario, Canada, which treats and tests about 100 newly diagnosed AML patients each year, conducted the quality improvement initiative to see if...
Acute myeloid leukemia (AML) diagnosis just got a significant speed boost. A cutting-edge algorithm dramatically reduces AML testing times, which means quicker results for patients. This breakthrough,incorporating flow cytometry and automated lab workflows,empowers physicians to make faster,more informed decisions,leading to personalized treatment plans—a crucial step in improving patient outcomes. News Directory 3 highlights the vital role of such advancements in transforming healthcare. This innovative approach prioritizes efficiency gains, offering hope to those affected by AML through faster analysis and more tailored therapeutic interventions. discover what’s next in the evolution of AML care.
AML Testing Algorithm Speeds Diagnosis, Personalized Treatment
Updated June 12, 2025
A new quality advancement project shows that using a flow cytometry-triggered genomic testing algorithm, along with automated laboratory processes, can greatly reduce the time it takes to get key molecular diagnostic results for patients newly diagnosed with acute myeloid leukemia (AML). This leads to quicker, more informed treatment choices, supporting personalized therapy and better patient care.
As AML classification increasingly relies on identifying genetically distinct subtypes, targeted therapies are being used earlier in treatment. Ideally,this induction treatment should start within five days of diagnosis. For example,gemtuzumab ozogamicin (mylotarg),an antibody-drug conjugate,might be added to induction chemotherapy. Randomized controlled trials have shown that patients receiving gemtuzumab ozogamicin had a five-year overall survival rate of 76.3%, compared to 55.2% for those who did not.
The London Health Science Center in Ontario, Canada, which treats and tests about 100 newly diagnosed AML patients each year, conducted the quality improvement initiative to see if a flow cytometry-triggered diagnostic testing algorithm could speed up genomic test ordering and reduce turnaround times.
Researchers focused on three key areas: educating clinicians and lab staff on current guidelines for managing newly diagnosed